China Blood Product Industry Report, 2015-2018
  • Apr.2015
  • Hard Copy
  • USD $2,650
  • Pages:128
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM064
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,800
  • Hard Copy + Single User License
  • USD $2,850

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises.

Amid the industrial prosperity and favorable policies, China’s production-use plasma volume broke through 4,000 tons and the total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human rabies immunoglobulin, human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively.

At the same time, the supply and R & D capabilities of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand have been intensified in recent years. In 2014, the lot release volume of the above two products ascended by 43.9% and 46.3% year on year respectively. Chengdu Rongsheng, Guangdong Danxia, Yuanda Shuyang, Shanxi Kangbao and other enterprises obtained clinical approval for their human blood coagulation factor VIII in 2014.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.3% to China’s production-use plasma volume and 33.6% to China’s blood product revenue in 2014.

Shanghai RAAS turns to be a Chinese blood product leader through two acquisitions. In 2014, it took over Banghe Pharmaceutical (now known as Zhengzhou RAAS) and TONROL for RMB1.8 billion and RMB4.758 billion separately, so that the blood product varieties of the company increased from 7 to 11, the number of plasma collection stations rose from 12 to 28, and its plasma collection capacity expanded from 400 tons to 900 tons.

?血制品 英文_副本.png

China Blood Product Industry Report, 2015-2018 focuses on the followings:
20120114.gifMarket characteristics, operating environments, status quo, etc. of China blood product industry;
20120114.gifSupply and demand, competitive landscape, import & export, development forecast, etc. of China blood product industry;
20120114.gifSupply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin.
20120114.gifOperation, blood product business and development prospects of 12 major Chinese blood product companies.

1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Product Industry
2.1 Market Size 
2.2 Status Quo 
2.3 Supply and Demand 
2.3.1 Supply 
2.3.2 Demand 
2.4 Market Competition 
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policy 
2.5.3 Domestic Biopharmaceutical Market
2.6 Import and Export 

3. Blood Product Market Segments in China
3.1 Human Albumin 
3.1.1 Supply and Demand 
3.1.2 Competitive Landscape 
3.1.3 Development Prospect 
3.2 Human Immunoglobulin (pH4) for Intravenous Injection 
3.2.1 Supply and Demand 
3.2.2Competitive Landscape 
3.3 Blood Coagulation Factor VIII 
3.3.1 Supply and Demand 
3.3.2 Competitive Landscape 
3.3.3 Development Prospect 
3.4 Hepatitis B Immunoglobulin 
3.4.1 Supply and Demand 
3.4.2Competitive Landscape 
3.5 Human Immunoglobulin 
3.5.1 Supply and Demand 
3.5.2 Competitive Landscape 
3.6 Human Prothrombin Complex 
3.6.1 Supply and Demand 
3.6.2 Competitive Landscape 
3.7 Tetanus Immunoglobulin 
3.7.1 Supply and Demand 
3.7.2Competitive Landscape 
3.8 Human Rabies Immunoglobulin  
3.8.1 Supply and Demand 
3.8.2 Competitive Landscape 

4. Major Chinese Manufacturers
4.1 China Biologic Products Inc. (NASDAQ: CBPO)
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure  
4.1.4 Customers and Suppliers 
4.1.5 R & D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Prospect and Forecast 
4.2 Hualan Biological Engineering Inc. (002007.SZ)
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin 
4.2.5 Customers and Suppliers 
4.2.6 R & D and Investment
4.2.7 Blood Products 
4.2.8 Prospect and Forecast 
4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
4.3.1 Profile 
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 Gross Margin 
4.3.5 Customers and Suppliers 
4.3.6 R & D and Investment
4.3.7 Prospect and Forecast 
4.4 Beijing Tiantan Biological Products Co., Ltd. (600161.SH)
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Customers and Suppliers 
4.4.5 Gross Margin 
.4.4.6 R & D and Investment 
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Prospect and Forecast 
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin 
4.5.5 Customers and Suppliers 
4.5.6 R & D and Investment 
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Prospect and Forecast 
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
4.6.1 Profile 
4.6.2 Operation 
4.6.3 Revenue Structure 
4.6.4 Gross Margin 
4.6.5 Customers and Suppliers 
4.6.6 R & D and Investment 
4.6.7 Prospect and Forecast 
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. 
4.7.1 Profile 
4.7.2 Blood Products 
4.8 Shanghai Institute of Biological Products Co., Ltd. 
4.8.1 Profile 
4.8.2 Blood Products 
4.9 Shanxi Kangbao Biological Product Co., Ltd. 
4.9.1 Profile 
4.9.2 Blood Products 
4.10 Green Cross 
4.10.1 Profile 
4.10.2 Blood Products 
4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.11.1 Profile 
4.11.2 Operation 
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.12.1 Profile 
4. 12.2 Operation 
4.12.3 Blood Products (Hebei Da’an Pharmaceutical Co., Ltd.)

5. Summary and Forecast
5.1 Company Analysis
5.2 Forecast
Basic Composition of Blood
Plasma Protein Separation Procedure
Classification and Efficacy of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Chinese and Overseas Recombinant Blood Products in Types
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Companies and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
Prices of Some Blood Products in China, 2014
Chinese Blood Product Market Size, 2003-2014
Lot Release Volume of Blood Products in China (by Product), 2008-2014
Blood Product Structure in China (by Lot Release Volume), 2009-2014
Annual Production-use Plasma Volume in China, 2002-2014
Geographical Distribution of Plasma Collection Stations in China by the End of 2014
Main Blood Products with Medical Insurance Coverage in China
Comparison between China and Developed Countries in Per Capita Consumption of Blood Products
Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Manufacturers in China, 2014
Product Line Comparison between Blood Product Manufacturers in China
Competitive Landscape of Global Blood Product Enterprises, 2013
Product Structure of Global Blood Products
Blood Products Available in Foreign Countries
Global Blood Product Manufacturers
Major Policies on Blood Products in China
Policies on Maximum Retail Prices of Drugs in China, 2014
Lot Release Volume of Imported Human Albumin in China, 2008-2014
Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
Ratio of Domestically-produced to Imported Human Albumin in China (by Lot Release Volume), 2007-2014
Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2014
Consumption of Human Immunoglobulin (pH4) for Intravenous Injection Per 1,000 People by Country, 2013  
Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2014
Price Comparison between Chinese and Overseas Human Immunoglobulin (pH4) for Intravenous Injection
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2014
Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2014 
Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2014
Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries
Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2014
Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Prices of Human Immunoglobulin in China by Dosage, 2014
Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2014 
Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2014
Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2014
Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2014
Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2014 
Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Equity Structure of China Biologic Products by the End of 2014
Distribution of Blood Product Production Bases and Plasma Stations of China Biologic Products, 2014
Revenue and Operating Income of China Biologic Products, 2007-2014
Gross Margin of China Biologic Products, 2011-2014
Revenue of China Biologic Products by Product, 2011-2014
Revenue Structure of China Biologic Products by Product, 2010-2014
Revenue of China Biologic Products from Top 5 Customers and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of China Biologic Products, 2010-2014
New Products of China Biologic Products under Research by the End of 2014
Lot Release Volume of Blood Products of Shandong Taibang, 2008-2014
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2008-2014
Lot Release Volume of Blood Products of Xi’an Huitian Blood Products, 2008-2014
Revenue and Operating Income of China Biologic Products, 2014-2018E
Revenue and Operating Income of Hualan Biological, 2007-2014
Revenue of Hualan Biological by Sector, 2007-2014
Gross Margin of Hualan Biological by Product, 2007-2014
Revenue of Hualan Biological from Top 5 Customers and % of Total Revenue, 2007-2014
Procurement of Hualan Biological from Top Five Suppliers and % of Total Procurement, 2007-2014
Name List and Procurement of Hualan Biological's Top 5 Suppliers, 2014
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2014
Varieties and Specifications of Blood Products of Hualan Biological
Plasma Collection Station Distribution of Hualan Biological by the End of 2014
Lot Release Volume of Blood Products of Hualan Biological, 2008-2014
Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2014
Revenue and Gross Margin of Hualan Biological by Product, 2007-2014
Revenue and Operating Income of Hualan Biological, 2014-2018E
Distribution of Plasma Collection Stations of Shanghai RAAS by the End of 2014
Revenue and Operating Income of Shanghai RAAS, 2008-2014
Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2014
Lot Release Volume of TONROL's Blood Products, 2008-2014   
Operating Revenue of Shanghai RAAS by Product, 2008-2014
Revenue of Shanghai RAAS by Region, 2008-2014
Gross Margin of Shanghai RAAS by Product, 2008-2014
Revenue of Shanghai RAAS from Top 5 Customers and % of Total Revenue, 2007-2014
Procurement of Shanghai RAAS from Top 5 Suppliers and % of Total Procurement, 2007-2014
R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2014
Revenue and Operating Income of Shanghai RAAS, 2014-2018E
Revenue and Profit of Tiantan Biological's Subsidiaries, 2014
Revenue and Operating Income of Tiantan Biological, 2007-2014
Revenue of Tiantan Biological by Sector, 2007-2014
Revenue of Tiantan Biological by Region, 2007-2014
Procurement of Tiantan Biological from Top 5 Suppliers and % of Total Procurement, 2008-2014
Revenue of Tiantan Biological from Top 5 Customers and % of Total Revenue, 2008-2014
Gross Margin of Tiantan Biological by Sector, 2008-2014
R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2014
Distribution of Blood Plasma Collection Stations of Tiantan Biological by the End of 2014
Revenue and Gross Margin of Blood Products of Tiantan Biological, 2007-2014
Lot Release Volume of Blood Products of Chengdu Rongsheng and Tiantan Biological, 2008-2013
Revenue and Operating Income of Tiantan Biological, 2014-2018E
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2014
Operating Revenue of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014
Gross Margin of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014
Revenue of Zhenxing Biopharmaceutical and Chemical from Top 5 Customers and % of Total Revenue, 2009-2014
Procurement of Zhenxing Biopharmaceutical and Chemical from Top 5 Suppliers and % of Total Procurement, 2013
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2014
Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2014
Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by Jun 2014
Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2014
Revenue and Gross Margin of Blood Products Business of Zhenxing Biopharmaceutical and Chemical, 2009-2014
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2018E
Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2014 
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2014
Revenue of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014
Lot Release Volume of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
Operating Revenue of Jiangxi Boya Bio-Pharmaceutical by Region, 2009-2014
Gross Margin of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014
Revenue of Jiangxi Boya Bio-Pharmaceutical from Top 5 Customers and % of Total Revenue, 2009-2013
Name List and Revenue Contribution of Top 5 Customers of Jiangxi Boya Bio-Pharmaceutical, 2014
Procurement of Jiangxi Boya Bio-Pharmaceutical from Top 5 Suppliers and % of Total Procurement, 2009-2014
R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2014
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2018E
Distribution of Blood Plasma Collection Stations of Yuanda Shuyang by the End of 2014
Lot Release Volume of Blood Products of Yuanda Shuyang, 2008-2014
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2014
Distribution of Blood Plasma Collection Stations of CNBG Shanghai Institute of Biological Products by the End of 2014
Distribution of Blood Plasma Collection Stations of Shanxi Kangbao Biological Product by the End of 2014
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2014 
Distribution of Blood Plasma Collection Stations of Green Cross China by the End of 2014
Lot Release Volume of Blood Products of Green Cross China, 2008-2014
Revenue and Operating Income of Humanwell Healthcare (Group), 2009-2014
Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2014
Production Industry Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2014
Revenue of Walvax Biotechnology by Sector, 2009-2014
Distribution of Plasma Stations of Major Blood Products Manufacturers in China by Dec 2014
Production-use Plasma Volume of Major Blood Product Manufacturers in China, 2014
Blood Product Revenue of Major Blood Product Manufacturers in China, 2011-2014
Main M & A Cases in China Blood Product Industry, 2008-2014
Chinese Blood Product Market Size, 2013-2018E
Gross Margin of Major Blood Products Manufacturers in China, 2011-2014

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号